After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Andrew Dunn

Senior Biopharma Correspondent

Simon Kohl turned an internship at Google DeepMind into a key role in building AlphaFold2, the Nobel Prize-winning AI model that predicts the structure of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Boston Pharma, building off MASH momentum, mulls an IPO ahead of Phase 3 trial

RFK Jr. convened roundtable around ways to reduce stem cell regulation

Sutro slashes workforce in half, changes CEO and closes factory

Pfizer terminates an early-stage STING agonist trial

MoonLake's CEO on its looming mid-year pivotal readout in skin disease

Obesity drug development—still room to grow

Af­ter help­ing build Al­phaFold, a 34-year-old first-time CEO launch­es his own AI biotech with $50M

Senior Biopharma Correspondent

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M